Revolution Medicines is trading at $186.50, down 4.01%, amid broader risk-off trading.
- No clear company-specific announcement on October 22 explains the decline; the latest notable company update was an October 20 Phase 3 trial start.
- Technology shares weakened over worries about AI spending, while rising oil prices added pressure to markets.
- This context is consistent with the provided declines in the S&P 500 and Nasdaq; no volume data was available.